Related Experiment Video
Updated: Nov 15, 2025

04:45
Use of Microscale Thermophoresis to Measure Protein-Lipid Interactions
Published on: February 10, 2022
7.5K
Novel Method for Quantifying AhR-Ligand Binding Affinities Using Microscale Thermophoresis.
Anne Stinn1,2, Jens Furkert3, Stefan H E Kaufmann1,4,5
1Department of Immunology, Max Planck Institute for Infection Biology, Charitéplatz 1, 10117 Berlin, Germany.
Biosensors
|March 6, 2021
Summary
We developed a new method to study how the aryl hydrocarbon receptor (AhR) binds to its natural ligands. This technique helps identify new drug candidates for diseases linked to AhR signaling.
Area of Science:
- Biochemistry and Molecular Biology
- Pharmacology and Drug Discovery
Background:
- The aryl hydrocarbon receptor (AhR) is a crucial cellular sensor for environmental pollutants and endogenous metabolites.
- AhR pathway dysregulation is linked to diseases like cancer and autoimmune disorders, making it a therapeutic target.
- Understanding AhR ligand binding is essential for developing targeted therapies and selective AhR modulators.
Purpose of the Study:
- To present a novel microscale thermophoresis-based assay for monitoring AhR ligand binding.
- To enable precise identification and characterization of unknown AhR ligands in a cell-free system.
- To establish a screening strategy for discovering selective AhR modulators.
Main Methods:
- Utilized microscale thermophoresis (MST) to measure binding interactions.
- Employed purified recombinant human AhR in a cell-free assay.
- Monitored the binding of AhR to its natural ligands.
Main Results:
- Successfully demonstrated a novel MST-based approach for AhR ligand binding analysis.
- The method allows for precise characterization of ligand interactions with purified AhR.
- Validated the approach for identifying and characterizing unknown AhR ligands.
Conclusions:
- The developed microscale thermophoresis assay is effective for studying AhR ligand binding.
- This method facilitates the discovery of novel AhR ligands and potential selective modulators.
- The approach supports targeted drug development for AhR-related diseases.

